GSK vs GRFS
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 23, 2026
GSK
GRFS
Investment Advisor Scores
GRFS
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | GRFS | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 21.2314 | 9.009 | GRFS |
| PEG Ratio | 106.1749 | 0.229 | GRFS |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.3% | -0.9% | GSK |
| Earnings Growth | -69.5% | 32.9% | GRFS |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 53.7/100 | 49.2/100 | GSK |
| Profit Margin | 14.5% | 6.1% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | BUY | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
MarkupPrice above SMA50, rising 50-day trend (0.7% over 20 days), RSI 54
GRFS
MarkupPrice above SMA50, rising 50-day trend (1.1% over 20 days), RSI 55
Fundamentals Snapshot
| Metric | GSK | GRFS |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.2 | 5.6 |
| Trailing P/E | 16.3 | 10.8 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.7% | 0.4% |
| Operating Margin | 0.3% | 0.2% |
| EPS | 3.19 | 0.74 |
| Dividend Yield | 0.04% | 0.03% |